Treatment of Bleeding Diathesis Associated with a Heparin-Like Anticoagulant in Plasma Cell Neoplasia Using Protamine
The development of a heparin-like anticoagulant (HLAC) in plasma cell neoplasia has previously been described in clinical literature. Testing of this HLAC, primarily in vitro, has demonstrated that neutralization may be achieved with protamine sulfate, owing to antithrombin III cofactor activity. We...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2018/4342301 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559236160159744 |
|---|---|
| author | Christopher A. Willner Mohammed M. Chisti |
| author_facet | Christopher A. Willner Mohammed M. Chisti |
| author_sort | Christopher A. Willner |
| collection | DOAJ |
| description | The development of a heparin-like anticoagulant (HLAC) in plasma cell neoplasia has previously been described in clinical literature. Testing of this HLAC, primarily in vitro, has demonstrated that neutralization may be achieved with protamine sulfate, owing to antithrombin III cofactor activity. We report a case in which intravenous protamine sulfate was administered to a patient with IgG-kappa monotypic multiple myeloma, which resulted in resolution of bleeding and coagulopathy, confirmed via objective laboratory data. Our case is intended to demonstrate that intravenous protamine sulfate should be considered in acute bleeding with plasma cell neoplasia. We review the literature to observe past experiences about this phenomenon. We postulate that chemotherapy, targeted therapies, and immunotherapies may also disrupt production of a HLAC. With further investigation, this strategy could be applicable in other hematological malignancies with bleeding diathesis, chiefly if the pathophysiology of the HLAC is precisely defined. |
| format | Article |
| id | doaj-art-b0bf795863574395872a7949cd08a479 |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-b0bf795863574395872a7949cd08a4792025-02-03T01:30:34ZengWileyCase Reports in Hematology2090-65602090-65792018-01-01201810.1155/2018/43423014342301Treatment of Bleeding Diathesis Associated with a Heparin-Like Anticoagulant in Plasma Cell Neoplasia Using ProtamineChristopher A. Willner0Mohammed M. Chisti1Department of Internal Medicine, Beaumont Royal Oak, Royal Oak, MI, USADepartment of Hematology and Oncology, Beaumont Royal Oak, Royal Oak, MI, USAThe development of a heparin-like anticoagulant (HLAC) in plasma cell neoplasia has previously been described in clinical literature. Testing of this HLAC, primarily in vitro, has demonstrated that neutralization may be achieved with protamine sulfate, owing to antithrombin III cofactor activity. We report a case in which intravenous protamine sulfate was administered to a patient with IgG-kappa monotypic multiple myeloma, which resulted in resolution of bleeding and coagulopathy, confirmed via objective laboratory data. Our case is intended to demonstrate that intravenous protamine sulfate should be considered in acute bleeding with plasma cell neoplasia. We review the literature to observe past experiences about this phenomenon. We postulate that chemotherapy, targeted therapies, and immunotherapies may also disrupt production of a HLAC. With further investigation, this strategy could be applicable in other hematological malignancies with bleeding diathesis, chiefly if the pathophysiology of the HLAC is precisely defined.http://dx.doi.org/10.1155/2018/4342301 |
| spellingShingle | Christopher A. Willner Mohammed M. Chisti Treatment of Bleeding Diathesis Associated with a Heparin-Like Anticoagulant in Plasma Cell Neoplasia Using Protamine Case Reports in Hematology |
| title | Treatment of Bleeding Diathesis Associated with a Heparin-Like Anticoagulant in Plasma Cell Neoplasia Using Protamine |
| title_full | Treatment of Bleeding Diathesis Associated with a Heparin-Like Anticoagulant in Plasma Cell Neoplasia Using Protamine |
| title_fullStr | Treatment of Bleeding Diathesis Associated with a Heparin-Like Anticoagulant in Plasma Cell Neoplasia Using Protamine |
| title_full_unstemmed | Treatment of Bleeding Diathesis Associated with a Heparin-Like Anticoagulant in Plasma Cell Neoplasia Using Protamine |
| title_short | Treatment of Bleeding Diathesis Associated with a Heparin-Like Anticoagulant in Plasma Cell Neoplasia Using Protamine |
| title_sort | treatment of bleeding diathesis associated with a heparin like anticoagulant in plasma cell neoplasia using protamine |
| url | http://dx.doi.org/10.1155/2018/4342301 |
| work_keys_str_mv | AT christopherawillner treatmentofbleedingdiathesisassociatedwithaheparinlikeanticoagulantinplasmacellneoplasiausingprotamine AT mohammedmchisti treatmentofbleedingdiathesisassociatedwithaheparinlikeanticoagulantinplasmacellneoplasiausingprotamine |